The global market for advanced drug delivery systems was valued at $248.2 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.5% from $262.6 billion in 2023 to reach $359.1 billion through 2028. Advances in therapeutics, the high prevalence of chronic diseases and rising innovations in material science will drive growth in this market. However, the advanced drug delivery systems (ADDS) market's growth will be hampered by a low acceptance of nanoparticles due to their potential risks and environmental concerns.
Based on technology, the advanced drug delivery systems (ADDS) market is segmented into immediate-release drug delivery, extended-release drug delivery, targeted-release drug delivery, delayed-release drug delivery, pulsatile-release drug delivery. Extended-release drug delivery dominates the market due to its usage in managing complex chronic diseases. The extended-release formulations offer enhanced patient adherence, more effective life-cycle management of pharmaceuticals and more long-term relief of symptoms by minimizing fluctuations in drug levels.
Based on the route of administration, the advanced drug delivery systems (ADDS) market is segmented into oral, parenteral/injectable, transmucosal, implant, transdermal, topical. The oral segment dominates the market. This can be attributed to the widespread use of the oral route in drug delivery due to the benefits associated with oral administration, including cost-effectiveness, minimal sterility constraints, flexibility in dosage form design and ease of production.
Based on drug vehicles/carriers, the ADDS market is segmented into nanoparticles, monoclonal antibodies, liposomes, polymer therapeutics, prodrugs, microparticles, other. The monoclonal antibodies segment will witness the highest CAGR due to the increasing incidence of cancers.
ADDS market has been segmented into oncology, respiratory, inflammatory and allergies, cardiovascular, ophthalmic, central nervous system, hormone replacement therapy and gynecology, viral and bacterial diseases, diabetes, urology, gastrointestinal disorders, dermatology, other based on application. The diabetes segment is poised to experience the highest CAGR due to the increasing incidence of diabetes and the introduction of smart insulin delivery devices in the market.
This report aims to provide a comprehensive study of the global market for advanced drug delivery systems (ADDS) and processes, both in terms of quantitative and qualitative data, to help people and companies develop business/growth strategies, assess the market landscape, analyze their position in the current marketplace and make informed business decisions about drug deliveries.
This in-depth analysis of the global ADDS market includes historical data and market projections on sales by technology, route of administration, drug vehicles/carriers and application. The analysis describes the different types of ADDS technology (immediate-release drug delivery, extended-release drug delivery, targeted-release drug delivery, delayed-release drug delivery, and pulsatile-release drug delivery) and their current and historical market revenues.
It also covers the route of administration of a drug delivery system and the source of a carrier mechanism for drug delivery. In addition, the report examines applications of ADDS (oncology, respiratory, inflammatory and allergies, cardiovascular, ophthalmic, central nervous system, hormone replacement therapy and gynecology, viral and bacterial diseases, diabetes, urology, gastrointestinal disorders, dermatology, other).
The Report Includes
27 data tables and 93 additional tables
An overview of the global markets and technologies for advanced drug delivery systems (ADDS)
Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
Estimate of the market size and revenue forecast for the global ADDS market, and corresponding market share analysis based on technology, application (therapeutic area), route of administration, vehicle/carrier of drugs mechanism and geographic region
Facts and figures pertaining to the market drivers, opportunities and challenges, emerging technologies and regulatory landscape
Discussion of the importance of ESG in the ADDS market, including consumer attitudes, impact of ESG factors on company performance and ESG practices of leading companies
Review of patents and patent applications filed on drug delivery release mechanisms and novel applications
Insight into the emerging technologies and developments in the ADDS market and clinical trial landscape
An analysis of the industry structure, including company market shares, recent M&A activity and venture funding
Analysis of the competitive landscape based on recent developments and the segmental revenues of leading vendors
Company profiles of major players within the industry, including Johnson & Johnson, Novartis AG, Pfizer Inc., Merck & Co. Inc., Medtronic, and Abbott.
Key Attributes:
Report Attribute
Details
No. of Pages
265
Forecast Period
2023 - 2028
Estimated Market Value (USD) in 2023
$262.6 Billion
Forecasted Market Value (USD) by 2028
$359.1 Billion
Compound Annual Growth Rate
6.5%
Regions Covered
Global
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
Evolution of Advanced Drug Delivery Systems
Chapter 4 Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the ADDS Market
Chapter 5 Evaluation of the Market Based on Technology
Market Share and Forecast
Immediate-Release Drug Delivery
Extended-Release Drug Delivery
Targeted-Release Drug Delivery
Delayed-Release Drug Delivery
Pulsatile-Release Drug Delivery
Chapter 6 Evaluation of the Market Based on Route of Administration
Market Share and Forecast
Oral
Parenteral/Injectable
Transmucosal
Transmucosal Nasal and Pulmonary
Transmucosal Ocular
Transmucosal Rectal
Transmucosal Oral Buccal
Transmucosal Vaginal
Implant
Transdermal
Topical
Chapter 7 Evaluation of the Market Based on Vehicle/Carrier
Market Share and Forecast
Nanoparticles
Monoclonal Antibodies
Liposomes
Polymeric Therapeutics
Dendrimers
Polymeric Drug
Polymeric Micelles
Prodrugs
Microparticles
Others
Chapter 8 Evaluation of the Market Based on Application
Market Share and Forecast
Oncology
Inflammatory Diseases and Allergies
Cardiovascular
Ophthalmic
Central Nervous System
Hormone Replacement Therapy and Gynecology
Viral and Bacterial Diseases
Diabetes
Urology
Gastrointestinal (GI) Disorders
Dermatology
Respiratory
Other Therapeutic
Chapter 9 Evaluation of the Market Based on Geographic Region
Chapter 10 ESG Development
Sustainability in the Advanced Drug Delivery Systems (ADDS) Industry: An ESG Perspective
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
